POPULATION PHARMACOKINETICS OF LEVODOPA AND CARBIDOPA FOLLOWING SUBCUTANEOUS INFUSION

被引：0
|
作者：
Birnberg, T. [1 ]
Adar, L. [1 ]
Smania, G. [2 ]
Bjornsson, M. [2 ]
Jonsson, N. [2 ]
Case, R. [2 ]
Karlsson, M. O. [3 ]
机构：
[1] NeuroDerm, Rehovot, Israel
[2] Pharmetheus, Uppsala, Sweden
[3] Uppsala Univ, Uppsala, Sweden
来源：
PARKINSONISM & RELATED DISORDERS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P 121
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics of levodopa/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson's disease
    Rosebraugh, M.
    Kym, P.
    Liu, W.
    Facheris, M.
    Benesh, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 838 - 838
  • [22] Pharmacokinetic-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Bjornsson, M.
    Karlsson, M.
    MOVEMENT DISORDERS, 2021, 36 : S162 - S162
  • [23] Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to Levodopa-Carbidopa Intestinal Gel delivered to the jejunum
    Rosebraugh, Matthew
    Stodtmann, Sven
    Liu, Wei
    Facheris, Maurizio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 331 - 331
  • [24] Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum
    Rosebraugh, Matthew
    Stodtmann, Sven
    Liu, Wei
    Facheris, Maurizio F.
    PARKINSONISM & RELATED DISORDERS, 2022, 97 : 68 - 72
  • [25] Foslevodopa/foscarbidopa Subcutaneous Infusion Maintains Equivalent Levodopa Exposure to Levodopa-Carbidopa Intestinal Gel Delivered to the Jejunum
    Rosebraugh, Matthew
    Stodtmann, Sven
    Liu, Wei
    Facheris, Maurizio
    NEUROLOGY, 2021, 96 (15)
  • [26] The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
    K. Jorga
    Barbel Fotteler
    Greg Sedek
    Thorkild Nielsen
    John Aitken
    Journal of Neurology, 1998, 245 : 223 - 230
  • [27] The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
    Jorga, K
    Fotteler, B
    Sedek, G
    Nielsen, T
    Aitken, J
    JOURNAL OF NEUROLOGY, 1998, 245 (04) : 223 - 230
  • [28] PHARMACOKINETICS OF CONTINUOUS-RELEASE CARBIDOPA/LEVODOPA
    SAGE, JI
    MARK, MH
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 : S1 - S6
  • [29] Baseline characteristics of the population enrolled to a randomized clinical study of subcutaneous levodopa/carbidopa (ND0612) infusion in patients with advanced PD
    Olanow, W.
    Ellenbogen, A.
    Djaldetti, R.
    Minei, T. Rachmilewitz
    Cohen, Y.
    Oren, S.
    Kieburtz, K.
    MOVEMENT DISORDERS, 2017, 32
  • [30] Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
    Othman, Ahmed A.
    Rosebraugh, Matthew
    Chatamra, Krai
    Locke, Charles
    Dutta, Sandeep
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (02) : 275 - 278
12345